HER2-fore undisclosed: Zymeworks mum on ZW-49 as Merck, BMS deals widen July 9, 2020 By Randy Osborne No Comments Zymeworks Inc.’s business update – which included a new, potential $891 million deal for multispecific antibody drugs with longtime partner Merck & Co. Inc. – drew mixed reviews from Wall Street, especially with regard to phase I prospect ZW-49.Read More